Aktuelle Ernährungsmedizin 2022; 47(03): 200-215
DOI: 10.1055/a-1555-5612
CME-Weiterbildung

Diagnostik und Therapie des Reizdarmsyndroms vom Diarrhö- und Mischtyp

Diagnosis and Therapy of Irritable Bowel Syndrome of the Diarrhea and Mixed Type
Bettina Mirgeler
,
Toktam Pour
,
Christian Sina

Symptome wie Diarrhö, Meteorismus und abdominale Schmerzen sind im klinischen Alltag häufig. Die Ursache ist oft das Reizdarmsyndrom (RDS). Während die Pathogenese noch unklar ist, wird die Pathophysiologie zunehmend besser verstanden. Im klinischen Alltag stellt die Diagnostik und Therapie des RDS eine große Herausforderung dar. Die heterogene Symptomatik und der Mangel an validierten Biomarkern erfordert eine umfassende Differenzialdiagnostik [1].

Abstract

Symptoms such as diarrhea, meteorism, and abdominal pain are common in everyday clinical practice. The cause is often irritable bowel syndrome (IBS). While the pathogenesis is still unclear, the pathophysiology of the disease is increasingly better understood. Irritable bowel syndrome can be divided into different subgroups. Particularly relevant for clinical practice are IBS with predominant constipation (IBS-C), IBS with predominant diarrhea (IBS-D), and IBS with mixed bowel habits (IBS-M). The diagnosis and therapy of IBS represent a major challenge. The heterogeneous symptoms and the lack of validated biomarkers require comprehensive differential diagnostics. This includes laboratory diagnostic, checking for food allergies, endoscopy, abdominal sonography, H2 breath tests, homocholic acid taurine tests, and psychosomatic diagnostic. There are different therapeutic approaches like nutrition therapy, administration of probiotics and symptom-oriented drug therapies. This article aims to give an overview of the diagnosis and therapy of IBSD and IBS-M in Germany with insights and experiences from clinical practice.



Publication History

Article published online:
14 June 2022

© 2022. Thieme. All rights reserved.

Georg Thieme Verlag
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Enck P, Aziz Q, Barbara G. et al. Irritable bowel syndrome. Nat Rev Dis Primers 2016; 2: 16014
  • 2 Rom IV Komitee. Rom IV Kriterien, Anhang A: Rom-IV-Diagnosekriterien für FGIDs. 4. Aufl. Rom: ROME FOUNDATION; 2016
  • 3 Oka P, Parr H, Barberio B. et al. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2020; 5: 908-917 Epub 2020. Erratum in: Lancet Gastroenterol Hepatol 2020; 5 (12): e8. PMID: 32702295
  • 4 Hauser W, Marschall U, Layer P. et al. The Prevalence, Comorbidity, Management and Costs of Irritable Bowel Syndrome. Dtsch Arztebl Int 2019; 116: 463-470
  • 5 Layer P, Andresen V, Pehl C. et al. Update S3-Leitlinie Reizdarmsyndrom: Definition, Pathophysiologie, Diagnostik und Therapie des Reizdarmsyndroms der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoff wechselkrankheiten (DGVS) und der Deutschen Gesellschaft für Neurogastroenterologie und Motilität (DGNM).. Z Gastroenterol: 2021. 59. 1323-1415
  • 6 Raskov H, Burcharth J, Pommergaard HC. et al. Irritable bowel syndrome, the microbiota and the gut-brain axis. Gut Microbes 2016; 7: 365-383
  • 7 Schemann M.. Reizdarm und Reizmagen – Pathophysiologie und Biomarker. Der Gastroenterologe 2017; 12: 114-129
  • 8 Saffouri GB, Shields-Cutler RR, Chen J. et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun 2019; 10: 2012
  • 9 Zhan K, Zheng H, Li J. et al. Gut Microbiota-Bile Acid Crosstalk in Diarrhea-Irritable Bowel Syndrome. Biomed Res Int 2020; 2020: 3828249
  • 10 Jabbar KS, Dolan B, Eklund L. et al. Association between Brachyspira and irritable bowel syndrome with diarrhoea. Gut 2021; 70: 1117-1129
  • 11 Tiffany CR, Bäumler AJ.. Dysbiosis: from fiction to function. Am J Physiol Gastrointest Liver Physiol 2019; 317: G602-G608
  • 12 Saffouri GB, Shields-Cutler RR, Chen J. et al. Small intestinal microbial dysbiosis underlies symptoms associated with functional gastrointestinal disorders. Nat Commun 2019; 10: 2012
  • 13 Fritscher-Ravens A, Pflaum T, Mösinger M. et al. Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E. Gastroenterology 2019; 157: 109-118.e5
  • 14 Arango Sancho P.. Complications of Phosphate and Vitamin D Treatment in X-Linked Hypophosphataemia. Adv Ther 2020; 37: 105-112
  • 15 Thomson AB, Sauve MD, Kassam N. et al. Safety of the long-term use of proton pump inhibitors. World J Gastroenterol 2010; 16: 2323-2330
  • 16 Husby S, Murray JA, Katzka DA.. AGA Clinical Practice Update on Diagnosis and Monitoring of Celiac Disease-Changing Utility of Serology and Histologic Measures: Expert Review. Gastroenterology 2019; 156: 885-889
  • 17 Raithel M, Hagel A, Albrecht H. et al. Excretion of urinary histamine and N-tele methylhistamine in patients with gastrointestinal food allergy compared to non-allergic controls during an unrestricted diet and a hypoallergenic diet. BMC Gastroenterol 2015; 15: 41
  • 18 Reese I, Ballmer-Weber B, Beyer K. et al. German guideline for the management of adverse reactions to ingested histamine: Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Association of Allergologists (AeDA), and the Swiss Society for Allergology and Immunology (SGAI). Allergo J Int 2017; 26: 72-79
  • 19 Manzotti G, Breda D, Di Gioacchino M. et al. Serum diamine oxidase activity in patients with histamine intolerance. Int J Immunopathol Pharmacol 2016; 29: 105-111
  • 20 Comas-Basté O, Sánchez-Pérez S, Veciana-Nogués MT. et al. Histamine Intolerance: The Current State of the Art. Biomolecules 2020; 10: 1181
  • 21 Valent P, Akin C, Arock M. et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol 2012; 157: 215-225
  • 22 Bojarski C, Tangermann P, Barmeyer C. et al. Prospective, double-blind diagnostic multicentre study of confocal laser endomicroscopy for wheat sensitivity in patients with irritable bowel syndrome. Gut 2021; gutjnl-2021-325181
  • 23 Oronsky B, Ma PC, Morgensztern D. et al. Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia 2017; 19: 991-1002
  • 24 Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS); Netzwerk Neuroendokrine Tumoren (NeT) e.V. (Patientenvertretung); Bundesorganisation Selbsthilfe NeuroEndokrine Tumoren e.V. (NET-sgh) (Patientenvertretung) et al. S2k-Leitlinie Neuroendokrine Tumore [Practice guideline neuroendocrine tumors - AWMF-Reg. 021-27]. Z Gastroenterol 2018; 56 : 583–5681. 10.1055/a-0604-2924
  • 25 Cicero G, Ascenti G, Bottari A. et al. MR enterography: what is next after Crohn’s disease?. Jpn J Radiol 2019; 37: 511-517
  • 26 Rana SV, Malik A.. Breath tests and irritable bowel syndrome. World J Gastroenterol 2014; 20: 7587-7601
  • 27 Simrén M, Stotzer PO.. Use and abuse of hydrogen breath tests. Gut 2006; 55: 297-303
  • 28 Fani B, Bertani L, Paglianiti I. et al. Pros and Cons of the SeHCAT Test in Bile Acid Diarrhea: A More Appropriate Use of an Old Nuclear Medicine Technique. Gastroenterol Res Pract 2018; 2018: 2097359
  • 29 Barkun AN, Love J, Gould M. et al. Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment. Can J Gastroenterol 2013; 27: 653-659
  • 30 Surdea-Blaga T, Baban A, Nedelcu L. et al. Psychological Interventions for Irritable Bowel Syndrome. J Gastrointestin Liver Dis 2016; 25: 359-366
  • 31 Grad S, Dumitrascu DL.. Irritable Bowel Syndrome Subtypes: New Names for Old Medical Conditions. Dig Dis 2020; 38: 122-127
  • 32 Bellini M, Tonarelli S, Nagy AG. et al. Low FODMAP Diet: Evidence, Doubts, and Hopes. Nutrients 2020; 12: 148
  • 33 Shepherd SJ, Gibson PR.. Fructose malabsorption and symptoms of irritable bowel syndrome: guidelines for effective dietary management. J Am Diet Assoc 2006; 106: 1631-1639
  • 34 Altobelli E, Del Negro V, Angeletti PM. et al. Low-FODMAP Diet Improves Irritable Bowel Syndrome Symptoms: A Meta-Analysis. Nutrients 2017; 9: 940
  • 35 Rastgoo S, Ebrahimi-Daryani N. Agah Shahram et al. Glutamine Supplementation Enhances the Effects of a Low FODMAP Diet in Irritable Bowel Syndrome Management. Frontiers in Nutrition 2021; 8: 1079
  • 36 Camilleri M.. Management Options for Irritable Bowel Syndrome. Mayo Clin Proc 2018; 93: 1858-1872
  • 37 Zong G, Lebwohl B, Hu FB.. Gluten intake and risk of type 2 diabetes in three large prospective cohort studies of US men and women. Diabetologia 2018; 61: 2164-2173
  • 38 Canakis A, Haroon M, Weber HC.. Irritable bowel syndrome and gut microbiota. Curr Opin Endocrinol Diabetes Obes 2020; 27: 28-35